{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:35:51Z","timestamp":1773693351260,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Japan Agency for Medical Research and Development","award":["20ck0106537h0001"],"award-info":[{"award-number":["20ck0106537h0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s13577-020-00425-8","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T12:03:01Z","timestamp":1599220981000},"page":"254-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor"],"prefix":"10.1007","volume":"34","author":[{"given":"Rei","family":"Noguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yoshimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Sei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwao","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-7792","authenticated-orcid":false,"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"425_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","volume":"88","author":"MJL Mastboom","year":"2017","unstructured":"Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88:688\u201394.","journal-title":"Acta Orthop"},{"key":"425_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","volume":"23","author":"V Ravi","year":"2011","unstructured":"Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23:361\u20136.","journal-title":"Curr Opin Oncol"},{"key":"425_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/00000637-198409000-00006","volume":"13","author":"RC Savage","year":"1984","unstructured":"Savage RC, Mustafa EB. Giant cell tumor of tendon sheath (localized nodular tenosynovitis). Ann Plast Surg. 1984;13:205\u201310.","journal-title":"Ann Plast Surg"},{"key":"425_CR4","volume-title":"Soft Tissue and Bone Tumours","author":"CDM Fletcher","year":"2020","unstructured":"Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. Soft Tissue and Bone Tumours. Geneva: WHO Press; 2020."},{"key":"425_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"425_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/CCO.0b013e328354c16b","volume":"24","author":"HT Temple","year":"2012","unstructured":"Temple HT. Pigmented villonodular synovitis therapy with MSCF-1 inhibitors. Curr Opin Oncol. 2012;24:404\u20138.","journal-title":"Curr Opin Oncol"},{"key":"425_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/gcc.20501","volume":"47","author":"E M\u00f6ller","year":"2008","unstructured":"M\u00f6ller E, Mandahl N, Mertens F, Panagopoulos I. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer. 2008;47:21\u20135.","journal-title":"Genes Chromosomes Cancer"},{"key":"425_CR8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1053\/jhsu.1999.1298","volume":"24","author":"KE Reilly","year":"1999","unstructured":"Reilly KE, Stern PJ, Dale JA. Recurrent giant cell tumors of the tendon sheath. J Hand Surg. 1999;24:1298\u2013302.","journal-title":"J Hand Surg"},{"key":"425_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","volume":"19","author":"H Gelderblom","year":"2018","unstructured":"Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19:639\u201348.","journal-title":"Lancet Oncol"},{"key":"425_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer. 2012;118:1649\u201355.","journal-title":"Cancer"},{"key":"425_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949\u201356.","journal-title":"Lancet Oncol"},{"key":"425_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394:478\u201387.","journal-title":"Lancet"},{"key":"425_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrc2820","volume":"10","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241\u201353.","journal-title":"Nat Rev Cancer"},{"key":"425_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"425_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740\u201354.","journal-title":"Cell"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1535-7163.MCT-15-0074","volume":"14","author":"BA Teicher","year":"2015","unstructured":"Teicher BA, Polley E, Kunkel M, et al. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther. 2015;14:2452\u201362.","journal-title":"Mol Cancer Ther"},{"key":"425_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25\u201338.","journal-title":"J Biomol Tech"},{"key":"425_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s13577-019-00312-x","volume":"33","author":"Y Yoshimatsu","year":"2020","unstructured":"Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 2020;33:427\u201336.","journal-title":"Hum Cell"},{"key":"425_CR19","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.27931","volume":"132","author":"A Capes-Davis","year":"2013","unstructured":"Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510\u20139.","journal-title":"Int J Cancer"},{"key":"425_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2016.03.013","volume":"163","author":"S Nath","year":"2016","unstructured":"Nath S, Devi GR. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther. 2016;163:94\u2013108.","journal-title":"Pharmacol Ther"},{"key":"425_CR21","doi-asserted-by":"publisher","first-page":"e0181340","DOI":"10.1371\/journal.pone.0181340","volume":"12","author":"A Voissiere","year":"2017","unstructured":"Voissiere A, Jouberton E, Maubert E, et al. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. PLoS ONE. 2017;12:e0181340.","journal-title":"PLoS ONE"},{"key":"425_CR22","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nrc1506","volume":"4","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Fukuoka M, Baselga J. Gefitinib\u2014a novel targeted approach to treating cancer. Nat Rev Cancer. 2004;4:956\u201365.","journal-title":"Nat Rev Cancer"},{"key":"425_CR23","doi-asserted-by":"crossref","unstructured":"Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991; 41:400\u201349.","DOI":"10.2165\/00003495-199141030-00007"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-020-00425-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T01:29:31Z","timestamp":1630718971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-020-00425-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1007\/s13577-020-00425-8","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of the Tochigi Cancer Center, and the National Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}